Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

GATM locus does not replicate in rhabdomyolysis study


Arising from L. M. Mangravite et al. Nature 502, 377–380 (2013); doi:10.1038/nature12508

All HMG-CoA reductase inhibitors (statins) can cause muscle injury ranging from asymptomatic elevations in creatine kinase levels to severe muscle breakdown (rhabdomyolysis) leading to kidney failure and death1, and the genetic variants responsible for this uncommon adverse drug reaction remain largely undiscovered. Mangravite et al. reported a new locus in the gene GATM (rs9806699) that was associated with a decreased risk of muscle injury in two case-control studies of myopathy (odds ratio, 0.60)2. In a larger case-control study of statin-related rhabdomyolysis, a more severe form of muscle injury, we were unable to replicate this finding. This failure to replicate raises questions about the role of GATM in statin-related muscle injury. There is a Reply to this Brief Communication Arising by Mangravite, L. M. et al. Nature 513, (2014).

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Thompson, P. D., Clarkson, P. & Karas, R. H. Statin-associated myopathy. J. Am. Med. Assoc. 289, 1681–1690 (2003)

    CAS  Article  Google Scholar 

  2. 2

    Mangravite, L. M., Engelhardt, B. E., Stephens, M. & Krauss, R. M. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502, 377–380 (2013)

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Marciante, K. D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 21, 280–288 (2011)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Floyd, J. S. et al. A screening study of drug–drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther. 91, 896–904 (2012)

    CAS  Article  Google Scholar 

  5. 5

    Staffa, J. A., Chang, J. & Green, L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 346, 539–540 (2002)

    Article  Google Scholar 

  6. 6

    Carr, D. F. et al. GATM gene variants and statin myopathy risk. Nature 513, (2014)

  7. 7

    Tamraz, B. et al. OATP1B1-related drug–drug and drug–gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis. Pharmacogenet. Genomics 23, 355–364 (2013)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Kameyama, Y., Yamashita, K., Kobayashi, K., Hosokawa, M. & Chiba, K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513–522 (2005)

    CAS  Article  Google Scholar 

  9. 9

    SEARCH Collaborative Group et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N. Engl. J. Med. 359, 789–799 (2008)

    Article  Google Scholar 

  10. 10

    Voora, D. et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609–1616 (2009)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11

    Linde, R., Peng, L., Desai, M. & Feldman, D. The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol. 2, 77–84 (2010)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12

    Carr, D. F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 94, 695–701 (2013)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13

    Fried, L. P. et al. The Cardiovascular Health Study: design and rationale. Ann. Epidemiol. 1, 263–276 (1991)

    CAS  Article  Google Scholar 

  14. 14

    Psaty, B. M. et al. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J. Clin. Epidemiol. 45, 683–692 (1992)

    CAS  Article  Google Scholar 

Download references

Author information




J.C.B. and J.S.F. carried out the analyses. B.M.P. obtained the funding for this work. J.S.F., F.C.B., J.A.B., S.R.H., K.R. and B.M.P. contributed to the design of the analyses and the drafting and revision of the manuscript.

Corresponding author

Correspondence to James S. Floyd.

Ethics declarations

Competing interests

B.M.P. serves on the data and safety monitoring board (DSMB) for a clinical trial of a device funded by the manufacturer (Zoll LifeCor).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Floyd, J., Bis, J., Brody, J. et al. GATM locus does not replicate in rhabdomyolysis study. Nature 513, E1–E3 (2014).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing